FDA Accepts and Grants Priority Review for AVYCAZ(R) (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)

Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Intra-Abdominal Infections (cIAI), in Combination with Metronidazole DUBLIN, Feb. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan ... Biopharmaceuticals, FDAAllergan, AVYCAZ , intra-abdominal infection, ceftazidime, avibactam

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2040850

Source: HSMN NewsFeed - February 24, 2016 Category: Pharmaceuticals Source Type: news